Loading...
XKRX196170
Market cap9.91bUSD
Dec 20, Last price  
277,000.00KRW
1D
-3.32%
1Q
-23.69%
Jan 2017
745.80%
IPO
1,120.26%
Name

Alteogen Inc

Chart & Performance

D1W1MN
XKRX:196170 chart
P/E
—
P/S
148.31
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
2.58%
Rev. gr., 5y
47.76%
Revenues
96.52b
+235.08%
3,959,773,5505,527,341,1107,042,577,9104,726,609,2496,843,719,83512,104,355,84313,703,078,87329,229,181,88342,425,842,45738,745,944,02728,806,344,49896,522,928,880
Net income
-3.37b
L-58.61%
1,433,818,3601,606,019,750931,144,4901,208,362,969-3,587,198,673-7,448,958,134-6,872,254,503-704,513,309-15,821,779,561-6,274,918,065-8,146,003,033-3,371,764,005
CFO
-7.77b
L-56.56%
1,230,719,1301,995,140,1701,210,050,1002,264,057,823-3,158,649,751-4,346,924,220-9,112,552,1269,133,183,9871,512,244,562-9,460,530,126-17,874,625,308-7,765,575,368
Earnings
Mar 10, 2025

Profile

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology. The company has a strategic alliance with Kissei Pharmaceutical to develop Aflibercept that has completed pre-clinical trial; and Cristalia for the development of Trastuzumab, which is in the Phase II clinical trial for the treatment of breast cancer. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
URL
http://www.alteogen.com/
IPO date
Dec 12, 2014
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
96,522,929
235.08%
28,806,344
-25.65%
38,745,944
-8.67%
Cost of revenue
95,650,777
51,411,579
49,063,557
Unusual Expense (Income)
NOPBT
872,152
(22,605,234)
(10,317,613)
NOPBT Margin
0.90%
Operating Taxes
17,834
108,049
893,168
Tax Rate
2.04%
NOPAT
854,318
(22,713,283)
(11,210,781)
Net income
(3,371,764)
-58.61%
(8,146,003)
29.82%
(6,274,918)
-60.34%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,391,270
2,139,826
445,845
BB yield
-0.05%
-0.11%
-0.01%
Debt
Debt current
292,417
84,725,187
113,547,012
Long-term debt
1,868,297
777,757
1,065,463
Deferred revenue
4,701,044
4,000,000
2,000,000
Other long-term liabilities
1,729,324
1,021,852
975,087
Net debt
(109,600,675)
(62,324,782)
(88,662,585)
Cash flow
Cash from operating activities
(7,765,575)
(17,874,625)
(9,460,530)
CAPEX
(43,455,494)
(42,547,966)
(30,524,628)
Cash from investing activities
(9,343,034)
50,612,431
(123,469,779)
Cash from financing activities
1,736,653
2,519,640
104,553,155
FCF
16,781,977
(28,329,702)
(21,326,568)
Balance
Cash
110,607,100
127,539,357
203,004,586
Long term investments
1,154,288
20,288,369
270,474
Excess cash
106,935,242
146,387,409
201,337,762
Stockholders' equity
45,864,943
44,498,110
(13,882,312)
Invested Capital
110,112,145
191,295,502
262,736,075
ROIC
0.57%
ROCE
0.56%
EV
Common stock shares outstanding
51,660
51,282
60,736
Price
98,500.00
157.52%
38,250.00
-49.47%
75,700.00
-36.81%
Market cap
5,088,497,294
159.41%
1,961,547,286
-57.34%
4,597,722,846
-49.18%
EV
4,978,624,091
1,896,293,994
4,506,613,161
EBITDA
4,205,682
(19,950,924)
(8,166,692)
EV/EBITDA
1,183.79
Interest
670,884
425,481
604,661
Interest/NOPBT
76.92%